Health Care • Biotechnology: Laboratory Analytical Instruments
$81.55 ▼ -2.07
(-2.47%)
MKT CAP: $10.63B • VOL: 1.86M
52W L $13 52W H $103
TXG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $642.8M | $610.8M | $618.7M |
| YoY Revenue Growth % | +5.2% | -1.3% | — |
| Gross Profit | $443.9M | $414.5M | $272.2M |
| Gross Margin % | 69.1% | 67.9% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$61.0M | -$194.6M | -$265.3M |
| Operating Margin % | -9.5% | -31.9% | -42.9% |
| Net Income (GAAP) | -$43.5M | -$182.6M | -$255.1M |
| EBITDA (Normalized) | -$56.2M | -$184.6M | -$243.1M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $136.1M | $6.7M | -$15.2M |
| Capital Expenditures (CapEx) | $5.9M | $12.4M | $27.8M |
| Free Cash Flow (FCF) | $130.1M | -$5.7M | -$43.0M |
| FCF Margin % | 20.2% | -0.9% | -7.0% |
| Return on Invested Capital (ROIC %) | -6.1% | -33.4% | -5.9% |
| Cash & Short-Term Equivalents | $114.6M | $344.1M | $642.8M |
| Total Debt (Short + Long Term) | $110.3M | $93.8M | $1.37B |
| Total Stockholders' Equity | $796.3M | $710.1M | $2.81B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TXG.